Hair loss treatments like Minoxidil, finasteride, and potential mRNA therapies are discussed. There is skepticism about targeting specific genes due to the complex genetic nature of hair loss.
Hair loss is linked to cellular physiology and the IGF-1 to TGF-B1 ratio, not just androgen sensitivity. The theory lacks evidence, while finasteride and minoxidil are effective treatments.
Hair loss is linked to DHT, with treatments like finasteride and minoxidil being common but not definitive. Economic interests influence research, and there is potential for new treatments like PP405 and RU58841.
Procapil is marketed as a natural hair loss treatment but lacks strong evidence and is industry-biased. Minoxidil and Finasteride are the only FDA-approved treatments for androgenetic alopecia.
The conversation discusses hair loss treatments, focusing on finasteride, minoxidil, and other options like PRP and ketoconazole. It highlights the importance of asking specific questions during a dermatology visit to determine the cause of hair loss and appropriate treatments.
Hair follicles usually go dormant rather than die, and treatments like finasteride, minoxidil, and hormone therapy can sometimes reactivate them, though results vary. Complete regrowth is rare, especially in long-term bald areas, but some individuals see significant improvement with these treatments.
Oral minoxidil is effective for hair loss but can cause cardiovascular side effects, such as pericardial effusion, especially in those with genetic predispositions. Starting with low doses and monitoring cardiovascular health are advised to reduce risks.
The conversation discusses why the difference between donor and balding hair isn't studied more to find a cure for hair loss. Treatments mentioned include Minoxidil, finasteride, and RU58841.
The "Big 3 Stack" for hair loss treatment, which includes Minoxidil for hair density improvement, Ketoconazole shampoo for enhancing hair volume and thickness, and Finasteride for blocking hair loss causing hormones. Microneedling can boost Minoxidil's effects.
Hair loss therapies focusing on hair follicle sugar metabolism and aldose reductase. Potential treatments include magnesium supplements, avoiding high glycemic index foods, and antioxidants.
Male androgenetic alopecia is commonly treated with topical minoxidil and oral finasteride, both requiring continuous use. Other options include hair restoration surgery, dutasteride, light therapy, and camouflaging agents.
HairClone is offering a DermalPapillaCell Hair Multiplication procedure in Guatemala, raising questions about its effectiveness and regulatory reasons for the location. Users express skepticism and curiosity about the treatment's success and potential costs.
A peptide from Japanese water chestnut fruit may help with hair loss by suppressing DHT's effect on hair follicle cell death, potentially serving as a finasteride alternative. The treatment's effectiveness and safety in humans remain uncertain.
Sildenafil (Viagra) shows potential for hair growth by enhancing dermalpapillacell proliferation and stimulating perifollicular vessel formation. Users discuss the possibility of using Cialis (tadalafil) similarly, noting its benefits and side effects.
Hair cloning and injection of dermalpapilla cells are discussed, with skepticism about their availability by 2023. Users mention Minoxidil, finasteride, and hair transplants as current treatments.
The conversation discusses a patent filed by Shiseido for cloning DermalPapilla (DP) cells to treat hair loss. The method involves using viral vectors to maintain the cells' growth-inducing properties, differing from Replicel's approach with Dermal Sheath Cup (DSC) cells.
AMP-303 and AMP-601 are new hair loss treatments targeting dermalpapilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.
Epibiotech will offer off-the-shelf allogeneic hair multiplication treatment in South Korea, using dermalpapilla cells from donors to grow hair in balding areas. This method is cheaper and less invasive than traditional hair transplants.
A Swiss product called Redensyl, which is supposed to target hair follicle stem cells and has recently been marketed in Europe. The post inquires if anyone has had any experience with the product.
DHT causes hair loss by driving cells into senescence, and a polyphenol in black chokeberry may reverse this. A product using this theory is being considered for use alongside finasteride, minoxidil, and microneedling.
HairClone is developing cell replacement treatments to rejuvenate and generate hair follicles, and has launched a crowdfunding campaign. A user expressed skepticism about the need for crowdfunding.
Improving hair health involves not only using treatments like finasteride, minoxidil, and ketoconazole but also focusing on a healthy lifestyle, including diet, exercise, and stress management. A balanced approach enhances treatment effectiveness and overall well-being.
HairClone aims to rejuvenate miniaturizing hair follicles through follicle banking and cell expansion, with treatments potentially available in the UK by 2022. The process involves extracting, storing, and cloning hair follicles, but full regenerative treatments will take many years to develop.
The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.
Japanese scientists discovered ABM cells, enabling successful human hair follicle cloning, potentially curing hair loss. The treatment may be available in Japan by 2028, but it will be expensive and require travel.
Microneedling may enhance hair regrowth by transferring stem cells to dormant follicles, improving the effects of minoxidil. Users discuss using microneedling with needle lengths around 1.5mm to stimulate hair growth.
A potential non-invasive topical treatment targeting the WNT Signaling Pathway for hair regeneration is being researched, with positive results on human hair follicle cells. Current effective treatments for hair loss include Minoxidil, finasteride, and hair transplantation.
Balding scalps have more androgen receptors, leading to increased TGF-beta, which causes blood vessel loss and hair follicle miniaturization. Blocking androgen signaling and TGF-beta may help prevent hair loss.
Hair regeneration and follicle cloning are considered far from being feasible, with current treatments like finasteride, minoxidil, and hair transplants expected to remain dominant for the next 15-20 years. Some are hopeful that AI advancements might accelerate progress, but many remain skeptical about significant breakthroughs in the near future.
CRISPR shows promise for treating hair loss by targeting specific genes. Current treatments include Minoxidil and finasteride, but CRISPR could offer a more precise solution, though it is still expensive and in early stages.